Skip to main content
. 2020 Nov 1;10(1):156–163. doi: 10.1002/cam4.3583

Table 2.

Summary of all grade 3–4 treatment‐related adverse events

Event %
Neutropenia 78.6
Thrombocytopenia 42.9
Anemia 35.7
Diarrhea 7.1
Febrile neutropenia 7.1
Hypokalemia 7.1
Hypophosphatemia 7.1